RT Journal Article
SR Electronic
T1 Proteome-Wide Assessment of Clustering of Missense Variants in Neurodevelopmental Disorders Versus Cancer
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.02.02.24302238
DO 10.1101/2024.02.02.24302238
A1 Ng, Jeffrey K.
A1 Chen, Yilin
A1 Akinwe, Titilope M.
A1 Heins, Hillary B.
A1 Mehinovic, Elvisa
A1 Chang, Yoonhoo
A1 Payne, Zachary L.
A1 Manuel, Juana G.
A1 Karchin, Rachel
A1 Turner, Tychele N.
YR 2024
UL http://medrxiv.org/content/early/2024/02/04/2024.02.02.24302238.abstract
AB Missense de novo variants (DNVs) and missense somatic variants contribute to neurodevelopmental disorders (NDDs) and cancer, respectively. Proteins with statistical enrichment based on analyses of these variants exhibit convergence in the differing NDD and cancer phenotypes. Herein, the question of why some of the same proteins are identified in both phenotypes is examined through investigation of clustering of missense variation at the protein level. Our hypothesis is that missense variation is present in different protein locations in the two phenotypes leading to the distinct phenotypic outcomes. We tested this hypothesis in 1D protein space using our software CLUMP. Furthermore, we newly developed 3D-CLUMP that uses 3D protein structures to spatially test clustering of missense variation for proteome-wide significance. We examined missense DNVs in 39,883 parent-child sequenced trios with NDDs and missense somatic variants from 10,543 sequenced tumors covering five TCGA cancer types and two COSMIC pan-cancer aggregates of tissue types. There were 57 proteins with proteome-wide significant missense variation clustering in NDDs when compared to cancers and 79 proteins with proteome-wide significant missense clustering in cancers compared to NDDs. While our main objective was to identify differences in patterns of missense variation, we also identified a novel NDD protein BLTP2. Overall, our study is innovative, provides new insights into differential missense variation in NDDs and cancer at the protein-level, and contributes necessary information toward building a framework for thinking about prognostic and therapeutic aspects of these proteins.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from the National Institutes of Health (R01MH126933 to T.N.T., R00MH117165 to T.N.T., P50HD103525 to T.N.T. as a Member and Scientific Liaison in the Washington University in St. Louis Intellectual and Developmental Disabilities Research Center), the ITCR program at the National Cancer Institute (U24CA258393 to R.K.), the Simons Foundation (Award #734069 to T.N.T.), and funds from the Washington University in St. Louis McDonnell Center for Cellular and Molecular Neurobiology to T.N.T.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used ONLY openly available human data that were originally located at: Turner TN, Wilfert AB, Bakken TE, Bernier RA, Pepper MR, Zhang Z, Torene RI, Retterer K, Eichler EE. Sex-Based Analysis of De Novo Variants in Neurodevelopmental Disorders. American journal of human genetics. 2019;105(6):1274-85. Epub 2019/12/02. doi: 10.1016/j.ajhg.2019.11.003. PubMed PMID: 31785789; PMCID: PMC6904808.; Kaplanis J, Samocha KE, Wiel L, Zhang Z, Arvai KJ, Eberhardt RY, Gallone G, Lelieveld SH, Martin HC, McRae JF, Short PJ, Torene RI, de Boer E, Danecek P, Gardner EJ, Huang N, Lord J, Martincorena I, Pfundt R, Reijnders MRF, Yeung A, Yntema HG, Vissers L, Juusola J, Wright CF, Brunner HG, Firth HV, FitzPatrick DR, Barrett JC, Hurles ME, Gilissen C, Retterer K. Evidence for 28 genetic disorders discovered by combining healthcare and research data. Nature. 2020;586(7831):757-62. Epub 2020/10/16. doi: 10.1038/s41586-020-2832-5. PubMed PMID: 33057194; PMCID: PMC7116826.; https://gdc.cancer.gov/about-data/publications/mc3-2017; https://cancer.sanger.ac.uk/cosmic/downloadI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript https://www.modelarchive.org/doi/10.5452/ma-tur-clump https://github.com/KarchinLab/CLUMP https://github.com/TNTurnerLab/3D-CLUMP https://github.com/TNTurnerLab/clustering_in_cancer_vs_ndd_paper